Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ArabinoFuranosylGuanineF-AraG

Radiopharmaceutical

Phase 1/2 Most advanced trial
1 Registered trials

What is ArabinoFuranosylGuanineF-AraG?

ArabinoFuranosylGuanineF-AraG is an investigational radiopharmaceutical studied in Advanced Cancer, Clear Cell Renal Cell Carcinoma.

At a glance

Also known as
ArabinoFuranosylGuanine [18F]F-AraG
Drug type
Radiopharmaceutical
Therapy area
Oncology
In trials of
TLX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05663710 Phase 1/2 Advanced Cancer Recruiting TLX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced CancerClear Cell Renal Cell Carcinoma

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.